US5399363A
(en)
*
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
US5346702A
(en)
*
|
1992-12-04 |
1994-09-13 |
Sterling Winthrop Inc. |
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
|
US5429824A
(en)
*
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
US5352459A
(en)
*
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
US5628981A
(en)
*
|
1994-12-30 |
1997-05-13 |
Nano Systems L.L.C. |
Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
|
DE69633222T2
(de)
*
|
1995-02-24 |
2005-09-08 |
Elan Pharma International Ltd. |
Nanopartikel-dispersionen enthaltende aerosole
|
US5785975A
(en)
*
|
1995-06-26 |
1998-07-28 |
Research Triangle Pharmaceuticals |
Adjuvant compositions and vaccine formulations comprising same
|
US20050267302A1
(en)
*
|
1995-12-11 |
2005-12-01 |
G.D. Searle & Co. |
Eplerenone crystalline form exhibiting enhanced dissolution rate
|
FR2742357B1
(fr)
*
|
1995-12-19 |
1998-01-09 |
Rhone Poulenc Rorer Sa |
Nanoparticules stabilisees et filtrables dans des conditions steriles
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
WO1998048847A1
(fr)
*
|
1997-04-25 |
1998-11-05 |
Nycomed Imaging As |
Composition de nanoparticules contenant une substance de contraste de rayons x iodee destinee a une sterilisation thermique
|
UA72189C2
(uk)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
US6337092B1
(en)
|
1998-03-30 |
2002-01-08 |
Rtp Pharma Inc. |
Composition and method of preparing microparticles of water-insoluble substances
|
AU761205B2
(en)
|
1998-03-30 |
2003-05-29 |
Skyepharma Canada Inc. |
Composition and method of preparing microparticles of water-insoluble substances
|
JP2002516267A
(ja)
|
1998-05-29 |
2002-06-04 |
アールティーピー・ファーマ・インコーポレーテッド |
熱的に保護された微粒子組成物及びその最終蒸気滅菌
|
IL141095A0
(en)
*
|
1998-08-19 |
2002-02-10 |
Rtp Pharma Inc |
Injectable aqueous dispersions of propofol
|
CA2346001C
(fr)
*
|
1998-10-01 |
2003-12-30 |
Elan Pharma International, Limited |
Liberation regulee de compositions nanoparticulaires
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US20070160675A1
(en)
*
|
1998-11-02 |
2007-07-12 |
Elan Corporation, Plc |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
HU230454B1
(hu)
*
|
1998-11-02 |
2016-07-28 |
Alkermes Pharma Ireland Limited |
Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
US20040141925A1
(en)
*
|
1998-11-12 |
2004-07-22 |
Elan Pharma International Ltd. |
Novel triamcinolone compositions
|
US6969529B2
(en)
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
BR9915738A
(pt)
|
1998-11-20 |
2001-10-02 |
Rtp Pharma Inc |
Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
|
US6267989B1
(en)
|
1999-03-08 |
2001-07-31 |
Klan Pharma International Ltd. |
Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
|
US6426145B1
(en)
|
1999-05-20 |
2002-07-30 |
Scimed Life Systems, Inc. |
Radiopaque compositions for visualization of medical devices
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US20090104273A1
(en)
*
|
1999-06-22 |
2009-04-23 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
ATE296091T1
(de)
*
|
1999-09-21 |
2005-06-15 |
Skyepharma Canada Inc |
Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
|
CN100413881C
(zh)
*
|
1999-12-08 |
2008-08-27 |
法马西亚公司 |
依匹乐酮晶形
|
SK12672001A3
(sk)
*
|
1999-12-08 |
2002-04-04 |
Pharmacia Corporation |
Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
US20030083493A1
(en)
*
|
1999-12-08 |
2003-05-01 |
Barton Kathleen P. |
Eplerenone drug substance having high phase purity
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
MY120279A
(en)
|
2000-05-26 |
2005-09-30 |
Pharmacia Corp |
Use of a celecoxib composition for fast pain relief
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
US8586094B2
(en)
*
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US20030224058A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
CA2436574A1
(fr)
*
|
2000-12-06 |
2002-06-13 |
Pharmacia Corporation |
Procede de broyage a echelle de laboratoire
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US6869617B2
(en)
*
|
2000-12-22 |
2005-03-22 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
EP1401401B1
(fr)
*
|
2001-06-22 |
2005-03-30 |
Marie Lindner |
Procede pour effectuer un criblage a haut rendement au moyen d'un broyeur de petite taille ou de procedes microfluidiques
|
US7758890B2
(en)
|
2001-06-23 |
2010-07-20 |
Lyotropic Therapeutics, Inc. |
Treatment using dantrolene
|
US20030073609A1
(en)
|
2001-06-29 |
2003-04-17 |
Pinkerton Thomas C. |
Enhanced pharmacokinetic profile of intradermally delivered substances
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
JP4464129B2
(ja)
*
|
2001-09-19 |
2010-05-19 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子インスリン製剤
|
EP1429772A1
(fr)
*
|
2001-09-25 |
2004-06-23 |
Pharmacia Corporation |
Formes a l'etat solide du n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
IL160570A0
(en)
*
|
2001-09-26 |
2004-07-25 |
Baxter Int |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
CA2463495C
(fr)
*
|
2001-10-12 |
2011-05-24 |
Elan Pharma International Ltd. |
Compositions combinant des caracteristiques de liberation immediate et de liberation prolongee
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
EP1450863A4
(fr)
*
|
2001-11-07 |
2009-01-07 |
Imcor Pharmaceutical Company |
Procedes d'imagerie vasculaire comprenant l'utilisation d'agents de contraste nanoparticulaires
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
PT1471887E
(pt)
*
|
2002-02-04 |
2010-07-16 |
Elan Pharma Int Ltd |
Composiães de nanopartculas com lisozima como um estabilizador superficial
|
US20040101566A1
(en)
*
|
2002-02-04 |
2004-05-27 |
Elan Pharma International Limited |
Novel benzoyl peroxide compositions
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
WO2003080027A1
(fr)
*
|
2002-03-20 |
2003-10-02 |
Elan Pharma International, Ltd. |
Compositions nanoparticulaires d'inhibiteurs d'angiogenese
|
US20030215502A1
(en)
*
|
2002-03-20 |
2003-11-20 |
Elan Pharma International Limited |
Fast dissolving dosage forms having reduced friability
|
WO2003082213A2
(fr)
*
|
2002-03-28 |
2003-10-09 |
Imcor Pharmaceutical Company |
Compositions et procedes de distribution d'agents pharmaceutiquement actifs au moyen de nanoparticules
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
US7101576B2
(en)
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
US9101540B2
(en)
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
PT1494649E
(pt)
|
2002-04-12 |
2012-04-11 |
Alkermes Pharma Ireland Ltd |
Formulações de megestrol em nanopartículas
|
EP1503737B1
(fr)
*
|
2002-05-06 |
2009-01-07 |
Elan Pharma International Limited |
Formulations de nystatine nanoparticulaires
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
CA2488498A1
(fr)
*
|
2002-06-10 |
2003-12-18 |
Elan Pharma International Limited |
Formulation de polycosanol nanoparticulaires et nouvelles combinaisons de polycosanol
|
WO2004006959A1
(fr)
*
|
2002-07-16 |
2004-01-22 |
Elan Pharma International, Ltd |
Compositions pour doses liquides d'agents actifs nanoparticulaires stables
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
CA2498207C
(fr)
|
2002-09-11 |
2012-03-13 |
Elan Pharma International Ltd. |
Compositions d'agents actifs nanoparticulaires stabilisees sous forme de gel
|
US20040105778A1
(en)
*
|
2002-10-04 |
2004-06-03 |
Elan Pharma International Limited |
Gamma irradiation of solid nanoparticulate active agents
|
US20040156895A1
(en)
*
|
2002-11-12 |
2004-08-12 |
Elan Pharma International Ltd. |
Solid dosage forms comprising pullulan
|
WO2004058216A2
(fr)
*
|
2002-12-17 |
2004-07-15 |
Elan Pharma International Ltd. |
Broyage de quantites de composes candidats nanoparticulaires de l'ordre du microgramme
|
JP4469846B2
(ja)
*
|
2003-01-31 |
2010-06-02 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子状トピラメート製剤
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
US8512727B2
(en)
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
US20100297252A1
(en)
*
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
JP2007501683A
(ja)
*
|
2003-05-22 |
2007-02-01 |
エラン ファーマ インターナショナル リミテッド |
γ線照射によるナノ粒子活性物質分散体の滅菌法
|
WO2005016310A1
(fr)
*
|
2003-08-08 |
2005-02-24 |
Elan Pharma International Ltd. |
Nouvelles compositions de metaxalone
|
NZ545744A
(en)
|
2003-09-22 |
2009-12-24 |
Baxter Int |
High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
|
CA2544627A1
(fr)
*
|
2003-11-05 |
2005-05-19 |
Elan Pharma International Ltd. |
Compositions nanoparticulaires comprenant un peptide comme stabilisant de surface
|
EP1730516A1
(fr)
*
|
2004-03-30 |
2006-12-13 |
Pfizer Products Incorporated |
Procede et dispositif pour l'evaluation de compositions pharmaceutiques
|
DK1731138T3
(en)
*
|
2004-03-31 |
2016-06-06 |
Toyama Chemical Co Ltd |
Fine dispersion of sparingly soluble drug and the process for preparing the
|
US20090004277A1
(en)
*
|
2004-05-18 |
2009-01-01 |
Franchini Miriam K |
Nanoparticle dispersion containing lactam compound
|
US7910577B2
(en)
*
|
2004-11-16 |
2011-03-22 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
US20090155331A1
(en)
*
|
2005-11-16 |
2009-06-18 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
UA89513C2
(uk)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Стабільна композиція з наночастинок ралоксифену гідрохлориду
|
KR20070116581A
(ko)
*
|
2004-12-15 |
2007-12-10 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 타크롤리무스 제제
|
WO2006069098A1
(fr)
*
|
2004-12-22 |
2006-06-29 |
Elan Pharma International Ltd. |
Formulations de la bicalutamide nanoparticulaire
|
EP1830824B1
(fr)
*
|
2004-12-31 |
2016-01-13 |
Iceutica Pty Ltd. |
Composition de nanoparticules et procedes de synthese de cette derniere
|
MX2007008212A
(es)
*
|
2005-01-06 |
2007-08-16 |
Elan Pharma Int Ltd |
Formulaciones de candesartan en nanoparticulas.
|
WO2006088894A2
(fr)
*
|
2005-02-15 |
2006-08-24 |
Elan Pharma International Limited |
Formulations aerosol et injectables de nanoparticules de benzodiazepine
|
CA2598288A1
(fr)
*
|
2005-03-03 |
2006-09-14 |
Elan Pharma International Limited |
Compositions nanoparticulaires de derives d'amide heterocyclique
|
WO2006099121A2
(fr)
*
|
2005-03-10 |
2006-09-21 |
Elan Pharma International Limited |
Preparations de finasteride, de dutasteride et de chlorhydrate de tamsulosine nanoparticulaires et de melanges de ceux-ci
|
JP2008533174A
(ja)
*
|
2005-03-16 |
2008-08-21 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子ロイコトリエン受容体拮抗薬/副腎皮質ステロイド製剤
|
CN101198316A
(zh)
*
|
2005-03-17 |
2008-06-11 |
伊兰制药国际有限公司 |
纳米微粒双膦酸盐组合物
|
MX2007011772A
(es)
*
|
2005-03-23 |
2007-12-05 |
Elan Pharma Int Ltd |
Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas.
|
US20070224282A1
(en)
*
|
2005-03-28 |
2007-09-27 |
Toyama Chemical Co., Ltd. |
Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
|
WO2006110809A2
(fr)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International, Limited |
Formulations inhibitrices de lipase nanoparticulaire
|
AU2006235487B2
(en)
*
|
2005-04-12 |
2011-12-22 |
Elan Pharma International Limited |
Nanoparticulate quinazoline derivative formulations
|
BRPI0609071A2
(pt)
*
|
2005-04-12 |
2010-11-16 |
Elan Pharma Int Ltd |
composicão estável de ciclosporina nanoparticulada, método para preparar uma ciclosporina nanoparticulada, uso da composição de ciclosporina nanoparticulada estável, e, composição de liberação controlada
|
WO2006132752A1
(fr)
*
|
2005-05-10 |
2006-12-14 |
Elan Pharma International Limited |
Compositions nanoparticulaires a liberation regulee comprenant de la vitamine k2
|
AU2006336417A1
(en)
*
|
2005-05-10 |
2007-08-02 |
Elan Pharma International, Limited |
Nanoparticulate clopidogrel formulations
|
KR20080026109A
(ko)
*
|
2005-05-16 |
2008-03-24 |
엘란 파마 인터내셔널 리미티드 |
세팔로스포린을 함유하는 나노입자형 조절 방출 조성물
|
US20100028439A1
(en)
*
|
2005-05-23 |
2010-02-04 |
Elan Pharma International Limited |
Nanoparticulate stabilized anti-hypertensive compositions
|
AU2006255177A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Elan Pharma International, Limited |
Nanoparticulate imatinib mesylate formulations
|
CA2610480A1
(fr)
*
|
2005-06-03 |
2007-05-10 |
Scott Jenkins |
Preparations nanoparticulaires a base d'acetaminophene
|
WO2006133045A1
(fr)
*
|
2005-06-03 |
2006-12-14 |
Elan Pharma International, Limited |
Préparations de benidipine nanoparticulaire
|
WO2008073068A1
(fr)
|
2005-06-08 |
2008-06-19 |
Elan Pharma International Limited |
Compositions à nanoparticules et à libération contrôlée comprenant du cefditoren
|
ES2335608T3
(es)
*
|
2005-06-09 |
2010-03-30 |
Elan Pharma International Limited |
Formulaciones de ebistina nanoparticuladas.
|
MX2007015882A
(es)
*
|
2005-06-13 |
2008-03-04 |
Elan Pharma Int Ltd |
Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
CA2608930A1
(fr)
*
|
2005-06-14 |
2006-12-28 |
Baxter International Inc. |
Preparations pharmaceutiques permettant de reduire les interactions entre medicaments
|
WO2006138421A2
(fr)
*
|
2005-06-15 |
2006-12-28 |
Elan Pharma International Limited |
Formulations d'azelnidipine nanoparticulaire
|
US20070015719A1
(en)
*
|
2005-07-07 |
2007-01-18 |
Elan Pharma International Limited |
Nanoparticulate clarithromycin formulations
|
CA2622200A1
(fr)
*
|
2005-09-13 |
2007-03-22 |
Elan Pharma International, Limited |
Formulations nanoparticulaires de tadalafil
|
EP1933814A2
(fr)
*
|
2005-09-15 |
2008-06-25 |
Elan Pharma International Limited |
Formulations aripiprazoliques nanoparticulaires
|
AU2006315177A1
(en)
*
|
2005-11-15 |
2007-05-24 |
Baxter Healthcare S.A. |
Compositions of lipoxygenase inhibitors
|
CA2631233C
(fr)
|
2005-11-28 |
2011-11-08 |
Marinus Pharmaceuticals |
Formes galeniques de ganaxolone et procedes de preparation et d'utilisation de celles-ci
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
EP2040675A1
(fr)
*
|
2006-05-30 |
2009-04-01 |
Elan Pharma International Limited |
Formulations de posaconazole nanoparticulaire
|
DK2054042T3
(da)
|
2006-06-30 |
2020-08-03 |
Iceutica Pty Ltd |
Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
|
CN104288103B
(zh)
*
|
2006-06-30 |
2019-10-15 |
伊休蒂卡有限公司 |
用于制备纳米粒形式的生物活性化合物的方法
|
CA2657379A1
(fr)
*
|
2006-07-10 |
2008-01-17 |
Elan Pharma International Ltd. |
Formulations de sorafenib nanoparticulaire
|
CL2007002689A1
(es)
|
2006-09-18 |
2008-04-18 |
Vitae Pharmaceuticals Inc |
Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
|
EP2101735A2
(fr)
|
2006-11-28 |
2009-09-23 |
Marinus Pharmaceuticals, Inc. |
Formulations de nanoparticules et procédés de préparation et d'utilisation de celles-ci
|
US20100062073A1
(en)
*
|
2006-11-29 |
2010-03-11 |
Ronald Arthur Beyerinck |
Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
|
US20090152176A1
(en)
*
|
2006-12-23 |
2009-06-18 |
Baxter International Inc. |
Magnetic separation of fine particles from compositions
|
US20100119612A1
(en)
*
|
2007-04-17 |
2010-05-13 |
Bend Research, Inc |
Nanoparticles comprising non-crystalline drug
|
US20100080852A1
(en)
*
|
2007-05-03 |
2010-04-01 |
Ronald Arthur Beyerinck |
Phamaceutical composition comprising nanoparticles and casein
|
US8703204B2
(en)
*
|
2007-05-03 |
2014-04-22 |
Bend Research, Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
|
US8309129B2
(en)
*
|
2007-05-03 |
2012-11-13 |
Bend Research, Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
US8722736B2
(en)
*
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
US20080293814A1
(en)
*
|
2007-05-22 |
2008-11-27 |
Deepak Tiwari |
Concentrate esmolol
|
US8426467B2
(en)
*
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
WO2008149230A2
(fr)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticules comprenant un médicament, un polymère cellulosique non ionisable et du tocophéryl polyéthylène glycol succinate
|
US8974827B2
(en)
*
|
2007-06-04 |
2015-03-10 |
Bend Research, Inc. |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
WO2009008391A1
(fr)
|
2007-07-06 |
2009-01-15 |
M.Technique Co., Ltd. |
Procédé de production de microparticules devant être ingérées dans le corps, microparticules devant être ingérées dans le corps et dispersion et composition médicinales les contenant
|
EP2178518A2
(fr)
*
|
2007-07-13 |
2010-04-28 |
Bend Research, Inc |
Nanoparticules comprenant des polymères cellulosiques ionisables faiblement solubles dans l'eau
|
US8642062B2
(en)
|
2007-10-31 |
2014-02-04 |
Abbott Cardiovascular Systems Inc. |
Implantable device having a slow dissolving polymer
|
EP2231169B1
(fr)
*
|
2007-12-06 |
2016-05-04 |
Bend Research, Inc. |
Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension
|
EP2240162A4
(fr)
*
|
2007-12-06 |
2013-10-09 |
Bend Res Inc |
Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine
|
US20090238867A1
(en)
*
|
2007-12-13 |
2009-09-24 |
Scott Jenkins |
Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
|
CA2715422A1
(fr)
*
|
2008-03-21 |
2009-09-24 |
Elan Pharma International Limited |
Compositions pour la delivrance d'imatinib specifique du site et procedes d'utilisation
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
TWI580441B
(zh)
*
|
2008-09-19 |
2017-05-01 |
愛爾康研究有限公司 |
穩定的藥學次微米懸浮液及其形成方法
|
DK3045043T3
(da)
|
2009-02-26 |
2020-08-03 |
Relmada Therapeutics Inc |
Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
|
US7828996B1
(en)
*
|
2009-03-27 |
2010-11-09 |
Abbott Cardiovascular Systems Inc. |
Method for the manufacture of stable, nano-sized particles
|
SG10201401695VA
(en)
|
2009-04-24 |
2014-08-28 |
Iceutica Pty Ltd |
A novel formulation of indomethacin
|
EP2253306A1
(fr)
|
2009-05-18 |
2010-11-24 |
Royal College of Surgeons in Ireland |
Formes de dosage orodispersibles contenant des dispersions de médicaments solides
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
EP3167875A1
(fr)
*
|
2009-05-27 |
2017-05-17 |
Alkermes Pharma Ireland Limited |
Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire
|
SG177281A1
(en)
|
2009-06-19 |
2012-02-28 |
Nanoform Hungary Ltd |
Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
|
AR077692A1
(es)
|
2009-08-06 |
2011-09-14 |
Vitae Pharmaceuticals Inc |
Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
|
US9012511B2
(en)
|
2010-05-19 |
2015-04-21 |
Alkermes Pharma Ireland Limited |
Nanoparticulate cinacalcet compositions
|
ES2625286T3
(es)
|
2011-07-22 |
2017-07-19 |
Chemocentryx, Inc. |
Una forma cristalina de la sal sódica de 4-terc-butil-n-[4-cloro-2-(1-oxi-piridin-4-carbonil)-fenil]-bencenosulfonamida
|
JP6166721B2
(ja)
|
2011-07-22 |
2017-07-19 |
ケモセントリックス, インコーポレイテッド |
4−tert−ブチル−N−[4−クロロ−2−(1−オキシ−ピリジン−4−カルボニル)−フェニル]−ベンゼンスルホンアミドのナトリウム塩の多形
|
CA2847066C
(fr)
|
2011-09-01 |
2019-04-30 |
Glaxo Group Limited |
Forme cristalline de rilapladib
|
US9056057B2
(en)
|
2012-05-03 |
2015-06-16 |
Kala Pharmaceuticals, Inc. |
Nanocrystals, compositions, and methods that aid particle transport in mucus
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
CA2871745C
(fr)
|
2012-05-03 |
2023-01-24 |
Kala Pharmaceuticals, Inc. |
Nanoparticules pharmaceutiques presentant un transport muqueux ameliore
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
US9251937B2
(en)
*
|
2012-06-29 |
2016-02-02 |
General Electric Company |
Heat stable nanoparticle preparations and associated methods thereof
|
US9526734B2
(en)
|
2014-06-09 |
2016-12-27 |
Iceutica Pty Ltd. |
Formulation of meloxicam
|
HUE054454T2
(hu)
|
2014-06-25 |
2021-09-28 |
Glaxosmithkline Ip Dev Ltd |
(S)-6-((1-Acetilpiperidin-4-il)amino)-N-(3-(3,4-dihidroizokinolin-2(1H)-il)-2- hidroxipropil)pirimidin-4-karboxamid kristályos sói
|
WO2016038519A1
(fr)
|
2014-09-08 |
2016-03-17 |
Glaxosmithkline Intellectual Property Development Limited |
Formes cristallines de 2-(4-(4-éthoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophényl)-n-(5-(1,1,1-trifluoro-2-méthylpropan-2-yl)isoxazol-3-yl)acétamide
|
CA2984421C
(fr)
|
2015-05-01 |
2024-04-09 |
Cocrystal Pharma, Inc. |
Analogues de nucleosides a utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
|
CA3001722A1
(fr)
|
2015-10-16 |
2017-04-20 |
Marinus Pharmaceuticals, Inc. |
Formulations injectables de neurosteroide contenant des nanoparticules
|
WO2017069712A1
(fr)
|
2015-10-22 |
2017-04-27 |
Sabanci Üniversitesi |
Système d'écoulement pour éviter l'agglomération de particules
|
KR102518846B1
(ko)
|
2016-08-11 |
2023-04-05 |
오비드 테라퓨틱스 인크. |
간질 장애의 치료를 위한 방법 및 조성물
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
WO2020118142A1
(fr)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone destiné à être utilisé dans la prophylaxie et le traitement de la dépression post-partum
|
WO2021026124A1
(fr)
|
2019-08-05 |
2021-02-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone destinée à être utilisée dans le traitement de l'état de mal épileptique
|
MX2022006014A
(es)
|
2019-12-06 |
2022-06-22 |
Marinus Pharmaceuticals Inc |
Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
|
CN115867259A
(zh)
|
2020-07-09 |
2023-03-28 |
詹森药业有限公司 |
长效配制品
|
CA3184868A1
(fr)
|
2020-07-09 |
2022-01-13 |
Rene Holm |
Formulations a action prolongee
|
WO2024068693A1
(fr)
|
2022-09-28 |
2024-04-04 |
Janssen Pharmaceutica Nv |
Formulations à action prolongée
|
WO2024068699A1
(fr)
|
2022-09-28 |
2024-04-04 |
Janssen Pharmaceutica Nv |
Formulations à action prolongée
|